抗凝的净益处在亚临床设备检测到的心房动
Aleksi K Winstén1,2, Ville Langén3, K E Juhani Airaksinen4
1Department of Mathematics and Statistics, University of Turku, Turku, Finland.
JAMA network open
|May 2, 2025
概括
对于设备检测到的亚临床心房 (AF) 患者,非维生素K对抗剂口服抗凝剂 (NOACs) 在预防中风方面提供了小而不确定的好处. 质量调整后寿命年 (QALYs) 的整体净益是最小的,并且在临床上没有显著意义.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 卫生经济学 卫生经济学
背景情况:
- 设备检测到的亚临床心房动 (AF) 对预防中风构成了困境.
- 在这些患者中,抗凝剂的净益仍然不确定.
研究的目的:
- 评估非维生素K对抗剂口服抗凝剂 (NOACs) 对设备检测的亚临床AF患者中风预防的净益.
- 评估NOAC对质量调整寿命 (QALY) 和临床结果的影响.
主要方法:
- 一个决策分析模型模拟了超过10年的NOAC和没有NOAC的10,000名患者.
- 马尔科夫决策模型包括中风风险,出血风险和死亡率数据.
- 进行了概率敏感性分析,以评估治疗效果不确定性的影响.
主要成果:
- NOAC治疗与21%的缺血性中风减少和1.1%的死亡减少有关.
- 然而,NOACs增加了主要出血事件的37.3%.
- 在10年内,QALYs的净收益约为每名患者0.024,表明收益最小.
结论:
- 在亚临床AF中启动NOAC显示了QALY的最小增加,但好处是不确定的.
- 在这个人群中,NOACs的整体净益可能没有临床意义.
- 需要进一步的研究来澄清亚临床AF的最佳管理策略.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
01:16Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K